On Friday, New Residential Investment Corp (NYSE:NRZ)’s shares declined -1.03% to $14.46.
NRG Energy, Inc. ( NRG ) stated second quarter Adjusted EBITDA of $729 million 1 , with $338 million from NRG Business and NRG Renew combined 5 , $204 million from NRG Home Retail, and $187 million from NRG Yield. Year-to-date adjusted cash flow from operations totaled $678 million. Net loss for the first six months of 2015 was $145 million, or $0.43 per diluted common share contrast to a net loss of $147 million, or $0.48 per diluted common share for the first six months of 2014.
NRG Business: Second quarter Adjusted EBITDA was $285 million; $16 million lower than in the second quarter 2014 primarily driven by:
- East Region: $11 million lower due to lower energy margins caused by milder weather and lower capacity revenues due to lower base residual auction prices and less capacity following plant deactivations, partially offset by lower operating costs due to fewer outages and reduced run time
- West Region: $26 million lower due to reduced pricing and a decline in contracted volumes from certain capacity contracts counting the retirement of Coolwater
- Gulf Coast Region: $27 million enhance due to higher realized energy margins, partially offset by raised outage costs during planned outages for fuel conversion and back-end control installations.
New Residential Investment Corp., a real estate investment trust (REIT), focuses on investing in and managing residential mortgage related assets. It operates through Servicing Related Assets, Residential Securities and Loans, and Other Investments segments. The company invests in excess mortgage servicing rights (MSRs) on residential mortgage loans; and in servicer advances, counting the basic fee component of the related MSRs.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s shares gained 0.46% to $15.19.
Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, recently declared financial results for the second quarter ended June 30, 2015. The Company also offered program updates and reiterated full-year 2015 net cash spend guidance of $100 million to $110 million.
Financial Highlights for Second Quarter Ended June 30, 2015
- Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015, contrast to $169.1 million at December 31, 2014.
- Total operating expenses raised to $26.9 million contrast to $14.7 million for the second quarter 2014, primarily due to enhances in preclinical and clinical development costs on the Fabry monotherapy and Pompe ERT programs.
- Net loss was $27.1 million, or $0.27 per share, contrast to a net loss of $14.6 million, or $0.22 per share, for the second quarter 2014.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I.
At the end of Friday’s trade, FirstEnergy Corp. (NYSE:FE)‘s shares surged 0.85% to $34.26.
FirstEnergy Corp. (FE) declared administration changes that expand the roles and responsibilities for key executives and support the company’s focus on customer service and cost administration. The changes will be effective by September 7, 2015.
Two members of the company’s leadership team have been named executive vice presidents. James H. Lash, president of FirstEnergy Generation, has been named executive vice president of FirstEnergy Corp. and president, FirstEnergy Generation. James F. Pearson, senior vice president and chief financial officer, has been named executive vice president and chief financial officer of FirstEnergy Corp. Both report to President and Chief Executive Officer Charles E. Jones.
FirstEnergy Corp., through its auxiliaries, generates, transmits, and distributes electricity in the United States. The company operates through Regulated Distribution, Regulated Transmission, and Competitive Energy Services segments. It owns and operates fossil, coal-fired, nuclear, oil and natural gas, wind and solar power, and hydroelectric generating facilities. The company also provides energy-related products and services to wholesale and retail customers.
FuelCell Energy Inc (NASDAQ:FCEL), ended its Friday’s trading session with -5.71% loss, and closed at $0.688.
FuelCell Energy, Inc. (FCEL), a global leader in the design, manufacture, operation and service of ultra‐clean, efficient and reliable fuel cell power plants, recently declared the appointment of two new members to the Company’s Board of Directors, counting Paul F. Browning, former President and Chief Executive Officer, Irving Oil Company Limited and Matthew F. Hilzinger, Executive Vice President and Chief Financial Officer, USG Corporation. These additions to the FuelCell Energy Board of Directors enhance the total number of members to ten.
FuelCell Energy, Inc., together its auxiliaries, designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation. The company is also involved in the development, design, production, and sale of fuel cell products under the Direct FuelCell name. Its power plants electrochemically produce electricity and heat using various fuels, counting natural gas, methanol, diesel, biogas, coal gas, coal mine methane, and propane.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
